These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 19841986)

  • 1. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling.
    Suzuki M; Wada H; Yoshino M; Tian L; Shigematsu H; Suzuki H; Alaa M; Tamura H; Fujiwara T; Nagato K; Motohashi S; Moriya Y; Hoshino H; Yoshida S; Shibuya K; Hiroshima K; Nakatani Y; Yoshino I
    Ann Surg Oncol; 2010 Mar; 17(3):878-88. PubMed ID: 19841986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer.
    Suzuki M; Shigematsu H; Nakajima T; Kubo R; Motohashi S; Sekine Y; Shibuya K; Iizasa T; Hiroshima K; Nakatani Y; Gazdar AF; Fujisawa T
    Clin Cancer Res; 2007 Oct; 13(20):6087-92. PubMed ID: 17947472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer.
    Suzuki M; Shigematsu H; Iizasa T; Hiroshima K; Nakatani Y; Minna JD; Gazdar AF; Fujisawa T
    Cancer; 2006 May; 106(10):2200-7. PubMed ID: 16598760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
    Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
    Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation.
    Tian L; Suzuki M; Nakajima T; Kubo R; Sekine Y; Shibuya K; Hiroshima K; Nakatani Y; Fujisawa T; Yoshino I;
    Cancer; 2008 Sep; 113(6):1396-403. PubMed ID: 18666211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
    Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.
    Brabender J; Danenberg KD; Metzger R; Schneider PM; Park J; Salonga D; Hölscher AH; Danenberg PV
    Clin Cancer Res; 2001 Jul; 7(7):1850-5. PubMed ID: 11448895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer.
    Kim DH; Nelson HH; Wiencke JK; Zheng S; Christiani DC; Wain JC; Mark EJ; Kelsey KT
    Cancer Res; 2001 Apr; 61(8):3419-24. PubMed ID: 11309302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
    Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
    Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage.
    Chan EC; Lam SY; Tsang KW; Lam B; Ho JC; Fu KH; Lam WK; Kwong YL
    Clin Cancer Res; 2002 Dec; 8(12):3741-6. PubMed ID: 12473584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG island methylator phenotype involving tumor suppressor genes located on chromosome 3p in non-small cell lung cancer.
    Liu Z; Zhao J; Chen XF; Li W; Liu R; Lei Z; Liu X; Peng X; Xu K; Chen J; Liu H; Zhou QH; Zhang HT
    Lung Cancer; 2008 Oct; 62(1):15-22. PubMed ID: 18358560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer.
    Miura N; Nakamura H; Sato R; Tsukamoto T; Harada T; Takahashi S; Adachi Y; Shomori K; Sano A; Kishimoto Y; Ito H; Hasegawa J; Shiota G
    Cancer Sci; 2006 Dec; 97(12):1366-73. PubMed ID: 17052260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p16(INK4A) Hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer.
    Bearzatto A; Conte D; Frattini M; Zaffaroni N; Andriani F; Balestra D; Tavecchio L; Daidone MG; Sozzi G
    Clin Cancer Res; 2002 Dec; 8(12):3782-7. PubMed ID: 12473590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
    Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
    Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.